GOVX
****Sponsored by LFG Equities Corp.
GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on the development of vaccines and immunotherapies addressing high-consequence infectious diseases and solid tumor cancer
GeoVax Announces Completion of Key GEO-MVA Development Milestones, Positioning Program for Pivotal Phase 3 Clinical Study
Manufacturing, Regulatory, Clinical and Preclinical Milestones Recently Completed in Support of Scheduled Fourth Quarter 2026 Initiation of Pivotal Immune-Bridging Study
READ THE INVESTOR PRESENTATION HERE
_________________________
Hello Everyone,
The market just opened and we want you to take a look at GOVX immediately.
GOVX is low priced, sitting well under $1 with interest starting to pick up.
GeoVax Labs (Nasdaq: GOVX) is making a calculated pivot to relevance as of late, positioning its existing vaccine science against one of the most urgent public health crises unfolding right now. The company recently announced that it's stepping forward to offer its expertise as the Democratic Republic of the Congo and surrounding region battle what the WHO is calling the fastest-growing Ebola outbreak ever recorded — this one caused by Bundibugyo virus, a strain with more than 4,300 cases and 2,000 deaths reported so far, and a trajectory that could eclipse the devastating 2014-2016 West Africa epidemic. Critically, there is currently no approved vaccine for Bundibugyo virus specifically, which is exactly the gap GeoVax is raising its hand to help fill.
What gives this recent announcement real weight rather than just opportunistic timing is GeoVax's actual track record with hemorrhagic fever viruses. The company has spent years building vaccine candidates on its Modified Vaccinia Ankara (MVA) platform — a well-established viral vector technology already used in approved vaccines elsewhere — targeting Zaire ebolavirus, Sudan ebolavirus, and Marburg virus. These candidates have gone through non-human primate lethal-challenge studies, which is about as serious as preclinical testing gets: animals are exposed to a normally fatal dose of the virus to see if the vaccine actually protects them, and GeoVax reports encouraging results. CEO David Dodd framed the company's posture plainly: they're prepared to engage with the WHO, Africa CDC, and national health authorities, and are willing to make vaccine materials available for evaluation against Bundibugyo virus specifically, even though a Bundibugyo-targeted candidate doesn't yet exist in their portfolio.
The more interesting strategic thread here, though, is how this connects to GeoVax's actual lead program, GEO-MVA — an MVA-based vaccine aimed at mpox and smallpox prevention, not Ebola. GeoVax is preparing a pivotal clinical trial for GEO-MVA using an accelerated "immunobridging" regulatory pathway (essentially, proving the new vaccine produces a comparable immune response to an already-approved MVA vaccine, rather than running a full efficacy trial from scratch), and portions of that trial are planned for African regions — including areas grappling with this very Ebola outbreak. In other words, GeoVax is already building relationships with regional health and research organizations for GEO-MVA's sake, and those same relationships happen to double as a natural entry point into the Ebola response conversation. Dodd was careful to frame this as additive rather than distracting: the Ebola outreach rides alongside existing GEO-MVA groundwork rather than pulling resources from it.
Beyond GEO-MVA, GeoVax is also floating its broader hemorrhagic fever portfolio as a source of "strategic optionality" — company language for saying these assets could become valuable through partnerships even if GeoVax doesn't fund their full development alone. The company says it is open to collaborations, licensing deals, and public-private partnerships that would bring in outside resources and expertise without diverting capital from its GEO-MVA priority.
The clinical-stage biotechnology company developing novel vaccines for many of the world's most threatening infectious diseases and therapies for solid tumor cancers. The company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine for which GeoVax was recently awarded a BARDA-funded contract to sponsor a 10,000-participant Phase 2b clinical trial to evaluate the efficacy of GEO-CM04S1 versus an approved COVID-19 vaccine. In addition, GEO-CM04S1 is currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. A Phase 2 clinical trial in first recurrent head and neck cancer, evaluating Gedeptin® combined with an immune checkpoint inhibitor is planned to initiate during the first half of 2025. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. The Company has a leadership team who have driven significant value creation across multiple life science companies over the past several decades.
The market is massive and the prospects are enormous.
Recently, Bavarian Nordic, a European vaccine maker of Mpox and Small Pox vaccines was offered $3B in a private equity buyout offer, which looks to be moving forward. In 2024, their MVA vaccine program generated $462M in revenue. This is not suggesting GeoVax will get a $3B buyout also, but is definitely indicative of the large potential of the market GeoVax is addressing and the strong interest from large industry players/investors.
GeoVax’s GEO-MVA candidate leverages a proprietary MVA vector to address the Mpox crisis and the ongoing threat of smallpox, offering broad protection, scalability, and resilience in vaccine supply. Unlike Bavarian Nordic, GeoVax is based in the U.S. and has invested heavily in a continuous cell line manufacturing process that supports large-scale, rapid, and cost-efficient production—an upgrade over traditional egg-based methods. This positions GeoVax to supply not only domestic needs but also bolster global pandemic preparedness and biosecurity, as recognized by recent favorable regulatory guidance from the European Medicines Agency (EMA) permitting a fast-tracked pathway to approval.
GeoVax Announces Completion of Key GEO-MVA Development Milestones, Positioning Program for Pivotal Phase 3 Clinical Study
Manufacturing, Regulatory, Clinical and Preclinical Milestones Completed in Support of Scheduled Fourth Quarter 2026 Initiation of Pivotal Immune-Bridging Study
ATLANTA, GA - August 6, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and solid tumors, today announced the completion of key manufacturing, regulatory, clinical and preclinical milestones supporting the initiation of its pivotal Phase 3 GEO-MVA immune-bridging study, scheduled to initiate in the fourth quarter of 2026.
"Completion of these milestones marks a significant inflection point for the GEO-MVA program as we prepare to initiate our pivotal immune-bridging study later this year," said David A. Dodd, Chairman and Chief Executive Officer of GeoVax. "We have systematically executed the manufacturing, regulatory, clinical and scientific activities required to support successful study completion, preparing for regulatory registration and ultimate commercialization."
Dodd continued, "Of special note, we recently completed a comparative nonclinical immunogenicity study evaluating GEO-MVA alongside the licensed MVA vaccine, Imvanex®, using both binding antibody and neutralizing antibody assays. The study demonstrated that GEO-MVA generated robust orthopoxvirus-specific immune responses. These findings further strengthen our confidence in GEO-MVA as we prepare to initiate our pivotal immune-bridging study later this year. Together with our manufacturing progress and favorable regulatory interactions, these data continue to support advancement of GEO-MVA into pivotal clinical evaluation.
"With GMP clinical product available and released, an expedited regulatory pathway established, clinical operations progressing and encouraging preclinical immunogenicity data in hand, we believe completion of these integrated milestones has substantially de-risked GEO-MVA and positions the program to advance into the Phase 3 study."
GEO-MVA is being developed to expand global manufacturing capacity for non-replicating MVA vaccine, supporting government preparedness programs and future procurement opportunities for this critically needed mpox/smallpox vaccine.
Key Development Milestones
Manufacturing Readiness: Successfully manufactured, filled, packaged and released GMP clinical product for use in the pivotal immune-bridging clinical study, completing a key requirement for clinical development.
Regulatory Alignment: Development strategy aligned with European Medicines Agency (EMA) Scientific Advice supporting an expedited immune-bridging pathway comparing GEO-MVA with the licensed MVA-BN vaccine.
Clinical Readiness: Advanced clinical operations through CRO engagement, and clinical site identification, supporting planned initiation of the targeted 500-participant study in the fourth quarter of 2026.
Preclinical Immunogenicity: A preclinical study generated neutralizing antibody data for GEO-MVA and MVA-BN that support the planned immune-bridging clinical strategy.
Commercial & Procurement Planning: In parallel with clinical development, GeoVax continues active discussions with government agencies and international preparedness organizations regarding future procurement opportunities and long-term MVA vaccine supply requirements.
GeoVax expects initiation of its targeted 500-participant immune-bridging clinical study during the fourth quarter of 2026. The study is designed to compare immune responses generated by GEO-MVA with those of the licensed MVA-BN vaccine using established neutralizing antibody endpoints. The Company expects to report results in mid-2027.
Additional CEO Commentary
GeoVax Chairman and Chief Executive Officer David Dodd provides additional context on the GEO-MVA development milestones, manufacturing readiness and planned Phase 3 study initiation.
About GEO-MVA
GEO-MVA is GeoVax's Modified Vaccinia Ankara (MVA)-based vaccine being developed for protection against mpox and smallpox. Following Scientific Advice from the European Medicines Agency (EMA), the program is advancing under an expedited immune-bridging clinical development strategy designed to compare immune responses generated by GEO-MVA with those of the licensed MVA-BN vaccine.
GeoVax is developing GEO-MVA to expand global access to MVA vaccine supply, scalable production capabilities, and a capital-efficient regulatory pathway. The Company believes GEO-MVA has the potential to become an important strategic preparedness asset by providing governments and international public health organizations with an additional, reliable source of MVA vaccine to support biosecurity and orthopoxvirus preparedness.
MVA TECHNOLOGY OVERVIEW
GeoVax’s vaccines are constructed to induce broader immunity through inclusion of multiple antigens into a single virus/vaccine platform. This is possible through the use of the company’s MVA vaccine platform, a large virus capable of incorporating multiple antigens into a vaccine platform.
Utilizing MVA, as a vaccine vector, allows for the targeting of multiple sites on a pathogen or cancer cell. Doing this is intended to result in a more robust and durable protective immune response. In addition, using MVA as a vaccine platform allows for the construction of vaccines which are capable of generating virus-like particles (VLPs) in the person receiving the vaccine.
The production of VLPs in the person being vaccinated is intended to mimic viral production that occurs in a natural infection, stimulating both the humoral (antibody) and cellular (T-cell) arms of the immune system to recognize, prevent, and control future infections.
MVA vectored vaccines can elicit durable (long-acting) immune responses while also possessing an excellent safety profile. MVA-VLP vaccines are designed to mimic authentic viruses in form but are not infectious or capable of replicating. As a result, VLPs can cause the body’s immune system to recognize and kill targeted infectious agents to prevent an infection or can be designed to target cancerous cells resulting in inhibited growth or destruction of tumors. VLPs can also train the immune system to recognize and kill virus-infected cells to control infection and reduce the length and severity of disease.
GEDEPTIN TECHNOLOGY OVERVIEW
A Phase 1/2 trial (NCT03754933), evaluating the safety and efficacy of repeat cycles of Gedeptin therapy in patients with recurrent head and neck squamous cell carcinoma (HNSCC), with tumor(s) accessible for injection and no curable treatment options recently completed enrollment at the Stanford University Cancer Institute, the Emory University Winship Cancer Institute, and the Thomas Jefferson University Sidney Kimmel Cancer Center.
The trial design involved repeat administration using Gedeptin followed by systemic fludarabine (prodrug). Expansion towards a larger, Phase 2 patient trial is anticipated. The FDA has granted Gedeptin orphan drug status for the intra-tumoral treatment of anatomically accessible oral and pharyngeal cancers, including cancers of the lip, tongue, gum, floor of mouth, salivary gland and other oral cavities. Also, the initial Phase 1/2 clinical study was funded by the FDA pursuant to its Orphan Products Clinical Trials Grants Program.
NEWS
GeoVax Chairman and CEO David Dodd to Participate in 2026 Georgia Life Sciences Summit
3 days ago•
GeoVax Highlights Capabilities Amid Congo's Expanding Ebola Outbreak
Aug 13, 2026•
GeoVax Highlights Gedeptin(R) Tumor-Priming Strategy as Immuno-Oncology Enters New Phase
Aug 11, 2026•
GeoVax Announces Completion of Key GEO-MVA Development Milestones, Positioning Program for Pivotal Phase 3 Clinical Study
Aug 6, 2026•
GeoVax Highlights Newly Published Independent Research Supporting Broader Filovirus Vaccine Strategies and Strategic Value of Its MVA-Based Vaccine Portfolio
Aug 3, 2026•
GeoVax Reports Second Quarter 2026 Financial Results and Provides Business Update
Jul 27, 2026•
GeoVax Highlights Strategic Alignment of GEO-MVA With HHS/ASPR's Five-Year Medical Countermeasure Preparedness Strategy
Jul 21, 2026•
GeoVax Highlights Continued U.S. Government Investment in Orthopox Preparedness as Strategic Validation of Long-Term Vaccine Readiness
Jul 1, 2026•
GeoVax Highlights Strategic Implications of Recent Gedeptin(R) Findings for Checkpoint-Resistant Cancers
Jun 17, 2026•
GeoVax Highlights Peer-Reviewed Research Supporting Gedeptin(R) Potential to Enhance Cancer Immunotherapy Responses
Jun 8, 2026
MANAGEMENT
Sincerely,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS A PUBLICATION OF ONE22 MEDIA, LLC, HEREIN REFERRED TO AS O22. O22’S REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATIONAL PURPOSES ONLY.O22 IS ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION.
O22 HAS BEEN COMPENSATED A FEE OF FIFTEEN THOUSAND USD BY A THIRD PARTY, LFG EQUITIES CORP FOR A ONE DAY GOVX PROFILE ON 8/24/26. O22 HAS PREVIOUSLY BEEN COMPENSATED A FEE OF TWENTY THOUSAND USD BY A THIRD PARTY, LFG EQUITIES CORP FOR A ONE DAY GOVX PROFILE ON 2/17/26. O22 HAS PREVIOUSLY BEEN COMPENSATED A FEE OF TWENTY THOUSAND USD BY A THIRD PARTY, LFG EQUITIES CORP FOR A ONE DAY GOVX PROFILE ON 9/21/25. O22 HAS PREVIOUSLY BEEN COMPENSATED A FEE OF TWENTY THOUSAND USD BY A THIRD PARTY, LFG EQUITIES CORP FOR A ONE DAY GOVX PROFILE ON 6/17/25. O22 HAS PREVIOUSLY BEEN COMPENSATED A FEE OF TWENTY THOUSAND USD BY A THIRD PARTY, LFG EQUITIES CORP FOR A ONE DAY GOVX PROFILE ON 3/3/25.
BY SUBSCRIBING TO OR OTHERWISE USING THIS WEBSITE/NEWSLETTER, YOU AGREE TO HOLD O22 AND ITS OPERATORS, OWNERS, AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS, DAMAGE, OR INJURY THAT YOU MAY INCUR, MONETARY OR OTHERWISE.
INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AN EXTREMELY HIGH DEGREE OF RISK. NEVER INVEST IN ANY STOCK FEATURED ON O22’S SITE OR NEWSLETTER UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING O22’S SERVICES, JOINING O22’S SITE OR EMAIL/BLOG LIST, OR FOLLOWING ANY SOCIAL NETWORKING PLATFORMS O22 MAY USE.
PLEASE NOTE WELL: O22 IS NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER. O22 IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES AND EXCHANGE COMMISSION, OR FINRA. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED.
THE INFORMATION CONTAINED HEREIN IS BASED ON INFORMATION SUPPLIED BY THE COMPANIES PROFILED, PUBLICLY AVAILABLE INFORMATION, PRESS RELEASES, AND OTHER SOURCES WHICH O22 BELIEVES TO BE RELIABLE, BUT IS NOT GUARANTEED BY O22 AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. O22 IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES PROFILED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE/NEWSLETTER IN DECIDING TO INVEST OR MAKE OTHER FINANCIAL DECISIONS. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE/NEWSLETTER AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. O22 STRONGLY ENCOURAGES READERS AND INVESTORS TO CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES, INCLUDING BY REVIEWING SEC FILINGS (FORMS 10-Q, 10-K, 8-K, 3, 4, 5, SCHEDULE 13D) AND BY CONSULTING YOUR OWN TAX, BUSINESS, FINANCIAL, AND INVESTMENT ADVISORS.
THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT, AND MAY BE FORWARD-LOOKING STATEMENTS. FORWARD-LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD-LOOKING STATEMENTS MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEES, EXPECTS, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, MAY, COULD, OR MIGHT. THERE IS NO GUARANTEE THAT PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS.